High expression of MAP7 (also known as ensconsin or E-MAP-115) has been reported to be an adverse prognostic biomarker for cytogenetically normal acute myeloid leukemia, stage II colon cancer, cervical cancer and metastatic endometrial cancer.39 Here, MAP7 is linked to cervical carcinoma.